Pfizer Ends Asenapine Collaboration With Organon
This article was originally published in The Pink Sheet Daily
Executive Summary
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
You may also be interested in...
Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.
Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.
Organon’s Asenapine Shows Less Weight Gain Than Zyprexa In Phase III Trial
Patients taking asenapine had approximately two-fold lower incidence of clinically significant weight gain; efficacy profile was similar to Lilly’s olanzapine.